Investment Manager Loads Up on CELC Stock, Adds 135,000 Shares, According to Latest SEC Filing
This clinical-stage biotech develops precision oncology therapies and diagnostics targeting unmet needs in breast and ovarian cancer.
📰 Original Source
Read full article at Fool →KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.